Literature DB >> 22874111

The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review.

Y Kikumoto1, H Sugiyama, H Morinaga, T Inoue, K Takiue, M Kitagawa, D Saito, Y Takatori, M Kinomura, S Kitamura, S Akagi, K Sada, K Nakao, Y Maeshima, H Kitayama, H Makino.   

Abstract

Fabry disease (FD) is an Xlinked disorder resulting in a deficiency in α-galactosidase A (α-Gal) activity. FD is one of the causes of progressive renal dysfunction, but its diagnosis is often delayed or missed completely. We herein report the case of a 70-year-old male who had been receiving hemodialysis (HD) for 23 y who was diagnosed with FD after his participation in a screening program for plasma α-Gal activity for 892 HD patients. He had a low plasma α-Gal activity level and was demonstrated to have an E66Q mutation in exon 2 of the α-Gal gene. One of his daughters had the same mutation. The proband died due to aspiration pneumonia before receiving enzyme replacement therapy. We reviewed previous studies and found E66Q mutation in 36% of Japanese FD patients on HD including the present case. The clinical characteristics of E66Q variant are also discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22874111     DOI: 10.5414/cn107097

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Role of the p.E66Q variant of GLA in the progression of chronic kidney disease.

Authors:  Hirofumi Watanabe; Shin Goto; Akinori Miyashita; Hiroki Maruyama; Minako Wakasugi; Akio Yokoseki; Ryozo Kuwano; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2014-04-10       Impact factor: 2.801

2.  Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST).

Authors:  Osamu Saito; Eiji Kusano; Tetsu Akimoto; Yasushi Asano; Teruo Kitagawa; Ken Suzuki; Nobuyuki Ishige; Takashi Akiba; Akira Saito; Eiji Ishimura; Motoshi Hattori; Akira Hishida; Chu Guili; Hiroki Maruyama; Masahisa Kobayashi; Touya Ohashi; Ichiro Matsuda; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2015-07-22       Impact factor: 2.801

3.  Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine.

Authors:  Hiroki Maruyama; Takuma Takata; Yutaka Tsubata; Ryushi Tazawa; Kiyoe Goto; Jun Tohyama; Ichiei Narita; Hidekatsu Yoshioka; Satoshi Ishii
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-10       Impact factor: 8.237

4.  Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.

Authors:  Masayoshi Oikawa; Nobuo Sakamoto; Atsushi Kobayashi; Satoshi Suzuki; Akiomi Yoshihisa; Takayoshi Yamaki; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-Ichi Saitoh; Yuichirou Kiko; Hajime Nakano; Takeharu Hayashi; Akinori Kimura; Yasuchika Takeishi
Journal:  BMC Cardiovasc Disord       Date:  2016-05-10       Impact factor: 2.298

5.  A Renal Variant of Fabry Disease Diagnosed by the Presence of Urinary Mulberry Cells.

Authors:  Homare Shimohata; Yujiro Ogawa; Hiroshi Maruyama; Kouichi Hirayama; Masaki Kobayashi
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

6.  Fabry disease in children: a federal screening programme in Russia.

Authors:  Leyla Seymurovna Namazova-Baranova; Alexander Alexandrovich Baranov; Aleksander Alekseevich Pushkov; Kirill Victorovich Savostyanov
Journal:  Eur J Pediatr       Date:  2017-09-04       Impact factor: 3.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.